Etifoxine (Stresam™) is an anxiety medication sold in France since 1979, and more than 25 other small countries around the world. However, it was never introduced into the United States or other major markets – and its patents have expired.
Clinically, it has the rapid onset and efficacy equivalent to Xanax and Ativan, two of the world’s top selling benzodiazepines, but without the sedation, cognitive impairment, withdrawal effects or abuse. To view a history of the drug, click here.
The unique combination of the drug’s selective effects at GABA channels, coupled with the ability to substantially increase the levels of important, natural neurosteroids (like allopregnanolone), give the drug an unrivaled anxiolytic profile of fast onset without the dangers or typical side-effects of benzodiazepines. Upregulation of neuroactive steroids by etifoxine may also account for its recently discovered neurotrophic, neuroprotective and anti-inflammatory properties.